LFST
$6.58
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States.
Recent News
3 Reasons LFST is Risky and 1 Stock to Buy Instead
Over the past six months, LifeStance Health Group has been a great trade, beating the S&P 500 by 22.7%. Its stock price has climbed to $6.58, representing a healthy 25.7% increase. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Healthcare Stocks We Think Twice About
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 4.1% over the past six months, almost identical to the S&P 500.
Should LifeStance Health’s Profit Turnaround And Capital Moves Require Action From LifeStance Health Group (LFST) Investors?
In February 2026, LifeStance Health Group, Inc. reported fourth-quarter 2025 revenue of US$382.2 million and full-year revenue of US$1.42 billion, turning a prior-year loss into net income of US$11.7 million for the quarter and US$9.66 million for the year while also authorizing a US$100 million share repurchase program and filing multiple common stock offerings and shelf registrations. Alongside issuing 2026 revenue guidance of US$380 million to US$400 million for the first quarter and...
Canaccord Lifts PT on LifeStance Health Group (LFST) to $10 From $9, Here’s Why
LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the best hot stocks under $20 to buy. On February 26, Canaccord lifted the price target on LifeStance Health Group, Inc. (NASDAQ:LFST) to $10 from $9 while keeping a Buy rating on the shares. The firm stated that fiscal Q4 results and 2026 guidance contemplate strong growth to […]
LifeStance Health Group Inc (LFST) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...
LifeStance Health Group Inc (LFST) reports robust financial performance with significant revenue and EBITDA growth, while outlining ambitious plans for new centers and technology investments in 2026.